This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sifting Through Small-Caps for Acquisition Targets

Bank of America Merrill Lynch thinks deal activity in 2012 will surpass 2011, which saw 99 deals in the small-cap space for a total of $84 billion, along with 35 mid-cap ($2 billion to $10 billion) deals, and that the pace of M&A could rival pre-financial crisis levels circa 2006-2007. In 2006, the firm said, there were 129 deals for small caps and 42 for mid caps.

According to Bank of America Merrill Lynch, tech and healthcare are likely to see the most buying interest, as they did in 2011 when nearly half of the deals were done in these two sectors.

To try to ascertain which specific Russell 2000 components could end up in play, Bank of America Merrill Lynch looked at valuation metrics for the companies that were bought in 2011 and ran a screen to see which names currently fit the bill.

The parameters used were market cap above $200 million, trailing five-year sales growth of more than 5%, net cash as a percent of market cap over 10%, a free cash flow yield of 8% and a long term debt to capital ratio below 30%. The stock also needed to be buy rated by the firm if it was under coverage.

The screen yielded 23 names, 10 from tech and 6 from healthcare. The firm notes that: "Our analysis should not be construed as any indication that any company on the list will be an actual candidate for a merger or acquisition."

Here's the list in full, broken down by sector: Caribou Coffee (CBOU) and Systemax (SYX), consumer discretionary; Cal-Maine Foods (CALM - Get Report), Medifast (MED - Get Report), Village Super Market (VLGEA), consumer staples; ArthoCare (ARTC), Depomed (DEPO), National Healthcare (NHC), RTI Biologics (RTIX), ViroPharma (VPHM), Wellcare Health Plans (WCG - Get Report), health care; Argan (AGX - Get Report) and Cubic Corp. (CUB), industrials; Entropic Communications (ENTR), j2 Global (JCOM - Get Report); LTX-Credence (LTXC), Nanometrics (NANO - Get Report), OmniVision Technologies (OVTI), Progress Software (PRGS - Get Report), Quest Software (QSFT), Rambus (RMBS - Get Report), Synaptics (SYNA), and Xyratex (XRTX), technology.

Of the group, the three largest market caps belong to Wellcare Health, $2.5 billion; ViroPharma, $2.1 billion; and Quest Software, $1.7 billion. The five companies with largest percentage of net cash to market cap, according to the firm's research, are Wellcare, 69.5%; Argan, 67.5%; OmniVision, 52.1%;; LTX-Credence, 44.1%; and Depomed, 31.9%, The names with the highest sales growth over the past 5 years are Entropic, 95.4%; Depomed, 73%; Argan, 45%; and Medifast, 40.7%.

-- Written by Michael Baron in New York.

>To contact the writer of this article, click here: Michael Baron.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
VPHM $49.96 -0.02%
ENTR $3.02 -2.27%
AGX $34.15 -1.01%
CALM $51.89 -0.99%
JCOM $63.54 -0.86%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs